IntoCell and Xcellon Biologics Partner to Advance Next-Generation ADC Development and Manufacturing

IntoCell Inc., a biotechnology company specializing in next-generation payload and linker technologies for antibody–drug conjugates (ADCs), has entered into a strategic collaboration with Xcellon Biologics, a U.S.-based contract development and manufacturing organization (CDMO) focused on ADCs and complex biologics. The partnership aims to accelerate ADC development and manufacturing by integrating complementary expertise and technologies.

Under the collaboration, IntoCell’s proprietary OHPAS drug-linker platform—featuring Duocarmycin and Nexatecan-based payloads—will be incorporated into Xcellon’s ADC development toolbox. Xcellon will provide bioconjugation, development, and manufacturing services to biotech and pharmaceutical companies utilizing IntoCell’s technologies in their ADC programs.

“We are pleased to collaborate with Xcellon Biologics, a leading CDMO company,” said Tae Kyo Park, CEO of IntoCell. “By combining IntoCell’s proprietary OHPAS linker and payload platforms with Xcellon’s bioconjugation and manufacturing expertise, we aim to help global innovators bring differentiated ADC therapies to patients faster.”

Abhishake Chhibber, Board Member of Xcellon Biologics, added, “Our vision is to make Xcellon a one-stop shop for early ADC and complex biologics development. Partnering with IntoCell strengthens that vision by giving our clients access to cutting-edge linker-payload technologies within a flexible, U.S.-based framework.”

Yuk Chiu, Co-Founder and COO of Xcellon Biologics, emphasized that the partnership “enhances Xcellon’s ADC toolbox and enables clients to explore a wider range of payload-linker combinations efficiently,” ultimately helping accelerate timelines for next-generation ADC programs.

The collaboration is designed to expand access to high-quality ADC technologies and streamline the path from discovery to manufacturing, supporting both companies’ missions to drive innovation in the rapidly evolving ADC field.